ReviewFrontiers in cellular neuroscience2021
Neurotropic Viruses, Astrocytes, and COVID-19.
Review in Frontiers in cellular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Neurological manifestations in patients with COVID-19: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- Understanding neuroinflammation in post-COVID-19 syndrome: biological mechanisms, diagnostic biomarkers, and therapeutic prospects.Translational psychiatry · 2026Review
- Layer-Specific Astrocyte Morphological Responses in the CA3 Hippocampus Region During Piry Virus-Induced Encephalitis.Hippocampus · 2026Article
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
- Pathogenic breaches: how viruses compromise blood-tissue barriers.Tissue barriers · 2026Review
- Neurological Symptoms as (Post) Pandemic Burden in Children and Adolescents-Single Tertiary Center Experience from Croatia.Iranian journal of child neurology · 2026Article
- Maternal COVID-19 infection associated with offspring neurodevelopmental disorders.Molecular psychiatry · 2025Article
- New perspectives on heterogeneity in astrocyte reactivity in neuroinflammation.Brain, behavior, & immunity - health · 2025Article
- Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025Review
- Heterogeneous Ribonucleoprotein K Is a Host Regulatory Factor of Chikungunya Virus Replication in Astrocytes.Viruses · 2024Article
- The Development of Epilepsy Following CNS Viral Infections: Mechanisms.Current neurology and neuroscience reports · 2024Review
- Review
- Review
- Astrocytes and the Psychiatric Sequelae of COVID-19: What We Learned from the Pandemic.Neurochemical research · 2023Review
- Mechanisms of Zika astrocyte infection and neuronal toxicity.NeuroImmune pharmacology and therapeutics · 2023Article
- RVG Peptide-Functionalized Favipiravir Nanoparticle Delivery System Facilitates Antiviral Therapy of Neurotropic Virus Infection in a Mouse Model.International journal of molecular sciences · 2023Article
- Nanosystems for gene therapy targeting brain damage caused by viral infections.Materials today. Bio · 2023Review
- Effective strategies against COVID-19 and the importance of infection sequelae.Global health research and policy · 2022Article
- An improved Fuzzy based GWO algorithm for predicting the potential host receptor of COVID-19 infection.Computers in biology and medicine · 2022Article
- In human astrocytes neurotropic flaviviruses increase autophagy, yet their replication is autophagy-independent.Cellular and molecular life sciences : CMLS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in China, causing a new coronavirus disease, termed COVID-19 by the WHO on February 11, 2020. At the time of this paper (January 31, 2021), more than 100 million cases have been recorded, which have claimed over 2 million lives worldwide. The most important clinical presentation of COVID-19 is severe pneumonia; however, many patients present various neurological symptoms, ranging from loss of olfaction, nausea, dizziness, and headache to encephalopathy and stroke, with a high prevalence of inflammatory central nervous system (CNS) syndromes. SARS-CoV-2 may also target the respiratory center in the brainstem and cause silent hypoxemia. However, the neurotropic mechanism(s) by which SARS-CoV-2 affects the CNS remain(s) unclear. In this paper, we first address the involvement of astrocytes in COVID-19 and then elucidate the present knowledge on SARS-CoV-2 as a neurotropic virus as well as several other neurotropic flaviviruses (with a particular emphasis on the West Nile virus, tick-borne encephalitis virus, and Zika virus) to highlight the neurotropic mechanisms that target astroglial cells in the CNS. These key homeostasis-providing cells in the CNS exhibit many functions that act as a favorable milieu for virus replication and possibly a favorable environment for SARS-CoV-2 as well. The role of astrocytes in COVID-19 pathology, related to aging and neurodegenerative disorders, and environmental factors, is discussed. Understanding these mechanisms is key to better understanding the pathophysiology of COVID-19 and for developing new strategies to mitigate the neurotropic manifestations of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.